SEC Company Response from Esperion Therapeutics, Inc. (ESPR) (CIK 0001434868) (ESPR) — Jun 21, 2013
Esperion Therapeutics, Inc. (ESPR) (CIK 0001434868)
Date: June 21, 2013 · CIK: 0001434868 · Accession: 0001104659-13-050692
AI Filing Summary & Sentiment
File numbers found in text: 333-188595
Letter
Credit Suisse Securities (USA) LLC
Eleven Madison Avenue
New York, New York 10010-3629
Citigroup Global Markets Inc.
388 Greenwich Street
New York, New York 10013
June 21, 2013
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn:
Jeffrey Riedler
Re:
Esperion Therapeutics, Inc.
Registration Statement on Form S-1
Registration File No. 333-188595
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representatives of the several Underwriters, hereby join in the request of Esperion Therapeutics, Inc. (the “Company”) for acceleration of the effective date of the above-named Registration Statement so that it becomes effective at 4:00 PM Eastern Time on June 25, 2013, or as soon thereafter as practicable or at such other time as the Company or its outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective.
Pursuant to Rule 460 under the Act, we, as representatives of the several Underwriters, wish to advise you that we have effected the following distribution of the Company’s Preliminary Prospectus dated June 12, 2013:
(i) Dates of distribution: June 12, 2013 through the date hereof
(ii) Number of prospective underwriters to which the preliminary prospectus was furnished: 4
(iii) Number of prospectuses furnished to investors: approximately 2,920
(iv) Number of prospectuses distributed to others, including the Company, the Company’s counsel, independent accountants, and underwriters’ counsel: approximately 271
We, the undersigned, as representatives of the several Underwriters, have complied and will comply, and we have been informed by the participating underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
Very truly yours,
CREDIT SUISSE SECURITIES (USA) LLC
Show Raw Text
CORRESP 1 filename1.htm Credit Suisse Securities (USA) LLC Eleven Madison Avenue New York, New York 10010-3629 Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 June 21, 2013 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Jeffrey Riedler Re: Esperion Therapeutics, Inc. Registration Statement on Form S-1 Registration File No. 333-188595 Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representatives of the several Underwriters, hereby join in the request of Esperion Therapeutics, Inc. (the “Company”) for acceleration of the effective date of the above-named Registration Statement so that it becomes effective at 4:00 PM Eastern Time on June 25, 2013, or as soon thereafter as practicable or at such other time as the Company or its outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective. Pursuant to Rule 460 under the Act, we, as representatives of the several Underwriters, wish to advise you that we have effected the following distribution of the Company’s Preliminary Prospectus dated June 12, 2013: (i) Dates of distribution: June 12, 2013 through the date hereof (ii) Number of prospective underwriters to which the preliminary prospectus was furnished: 4 (iii) Number of prospectuses furnished to investors: approximately 2,920 (iv) Number of prospectuses distributed to others, including the Company, the Company’s counsel, independent accountants, and underwriters’ counsel: approximately 271 We, the undersigned, as representatives of the several Underwriters, have complied and will comply, and we have been informed by the participating underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended. Very truly yours, CREDIT SUISSE SECURITIES (USA) LLC CITIGROUP GLOBAL MARKETS INC. Acting severally on behalf of themselves and the several Underwriters By: CREDIT SUISSE SECURITIES (USA) LLC By: /s/ Charles W. Newton Name: Charles W. Newton Title: Managing Director By: CITIGROUP GLOBAL MARKETS INC. By: /s/ Christopher Hite Name: Christopher Hite Title: Managing Director, Global Head — Healthcare [Signature Page to Underwriters’ Acceleration Request]